Covid-19 Tedavi Stratejileri

T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü (2020). Bilimsel Danışma kurulu çalışması. COVID-19 (SARS-CoV-2 Enfeksiyonu) Genel bilgiler, Epidemiyoloji ve Tanı (2020). Güncelleme Tarihi: 27 Kasım 2020 (05.01.2021 tarihinde https://covid19.saglik.gov.tr/Eklenti/39551/0/covid19rehberigenelbilgilerepidemiyolojivetanipdf.pdf adresinden ulaşılmıştır).

Worldometer (2020). Coronavirus (COVID-19) Mortality Rate (2020). (06.01.2021 tarihinde https://www.worldometers.info/coronavirus/coronavirus-death-rate/ adresinden ulaşılmıştır).

Ioannidis J. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bulletin of the World Health Organization 2021;99:19-33F.

Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci 2020; 24: 12593-12608.

Siddiqi HK., Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J Heart Lung Transplant. 2020; 39(5): 405–407.

Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019–COVID-19. Clin Microbiol Rev. 2020; 33(4): e00028-20.

Cron RQ, Chatham W. The Rheumatologist’s Role in Covid-19. J Rheumatol 2020;47(5):639-642.

Fantini J, Di Scala C, Chah inian H, Yah i N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents 2020; 55: 105960.

Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol 2011; 38: 2504-2508.

Gao, J., Tian, Z. & Yang, X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14, 72–73.

Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, International Journal of Antimicrobial Agents 2020;56 (1):105949

Lenzer, J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 2020;369:m1335

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020; 382: 2411-8. DOI: 10.1056/NEJMoa2012410

Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA 2020;323(24):2493-2502.

FDA (2020). Frequently Asked Questions on the Emergency Use Authorization (EUA) for Chloroquine Phosphate and Hydroxychloroquine Sulfate for Certain Hospitalized COVID-19 Patients (2020). (07.01.2021 tarihinde https://www.fda.gov/media/136784/download adresinden ulaşılmıştır).

Chu CM, Cheng VC, Hung IFN, Wong MML, Chan KH, Chan KS et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6. doi: 10.1136/thorax.2003.012658.

Tırmıkcıoglu Z. COVID-19 Enfeksiyonu Olan Gebelerde İlaç Kullanımı. Anadolu Kliniği Tıp Bilimleri Dergisi 2020;25 (Özel Sayı 1):51-58.

Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci 2020;35(6):e79. DOI: 10.3346/jkms.2020.35.e79

Wen CY, Xie ZW, Li YP, Deng XL, Chen XT, Cao Y, et al. [Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19 : an observational cohort study]. Zhonghua Nei Ke Za Zhi 2020 May 9;59(0):E012.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382: 1787-1799.

RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–52. doi: 10.1016/S0140-6736(20)32013-4.

Hoofnagle JH, Seeff LB. Peginterferon and Ribavirin for Chronic Hepatitis C. N Engl J Med 2006;355:2444-51.

Wang, M., Cao, R., Zhang, L. Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–271.

Martinez MA. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Antimicrob Agents Chemother 2020;64(5):e00399-20. DOI: 10.1128/AAC.00399-20

Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 2021;102:501-508. doi: 10.1016/j.ijid.2020.10.069.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing) 2020;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007.

Chen C, Zhang Y, Huang J, . Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv 2020.03.17.20037432. doi: 10.1101/2020.03.17.20037432.

Udwadia ZF, Singh P, Barkate H, Patil S, RangWala S, Pendse A et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis 2020;103:62-71. Doi:10.1016/j.ijid.2020.11.142

FUJIFILM (2020). Anti-influenza drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients (2020). (10.01.2021 tarihinde https://www.fujifilm.com/sg/en/news/hq/5451 adresinden ulaşılmıştır).

Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19: 149-150. doi: 10.1038/d41573-020-00016-0.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9.

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 2020 Nov 5;383(19):1827. DOI: 10.1056/NEJMoa2015301

Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA 2020;324(11):1048-1057. doi:10.1001/jama.2020.16349

US Food and Drug Administration (2020). FDA Approves First Treatment for COVID-19 (2020). (11.01.2021 tarihinde https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 adresinden ulaşılmıştır).

WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2020 Dec 2:NEJMoa2023184. doi: 10.1056/NEJMoa2023184.

Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM et al. Convalescent plasma: new evidence for an old therapeutic tool?. Blood Transfus 2016;14(2):152-157. doi:10.2450/2015.0131-15

Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015;211:80–90. doi: 10.1093/infdis/jiu396.

Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020;324(5):460–470. doi: 10.1001/jama.2020.10044.

Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES,et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv 2020;2020.08.12.20169359. doi: https://doi.org/10.1101/2020.08.12.20169359

FDA (2020). Investigational COVID‐19 convalescent plasma—emergency (2020). (12.01.2021 tarihinde https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds adresinden ulaşılmıştır).

Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc 2020 Sep;95(9):1888-1897. Doi: 10.1016/j.mayocp.2020.06.028

Bass J, Singh A, Williams R Lindner DH. Procalcitonin and COVID-19: A Reliable Clinical Tool, PREPRINT (Version 1) 15.01.2021 tarihinde https://www.researchsquare.com/article/rs-43706/v1 adresinden ulaşılmıştır). DOI: 10.21203/rs.3.rs-43706/v1

Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol 2020;2(10):e594-e602. Doi: 10.1016/S2665-9913(20)30275-7.

Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324(13):1317-1329. doi: 10.1001/jama.2020.17022.

Dequin PF, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 2020;324(13):1298-1306. doi: 10.1001/jama.2020.16761.

Monreal E, Sainz de la Maza S, Natera-Villalba E, Beltrán-Corbellini Á, Rodríguez-Jorge F, Fernández-Velasco JI, et al. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2020:1–9. doi: 10.1007/s10096-020-04078-1.

Liu J, Zhang S, Dong X, Li Z, Xu Q, Feng H, et al. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Invest. 2020;130(12):6417-6428. doi: 10.1172/JCI140617

RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020:NEJMoa2021436. doi: 10.1056/NEJMoa2021436.

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330-1341. doi: 10.1001/jama.2020.17023.

Atalay S, Ersan G. COVID-19 Tedavisi. Tepecik Eğit. ve Araşt. Hast. Dergisi 2020;30(Ek sayı):126-34.

Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020;ciaa954. doi: 10.1093/cid/ciaa954.

Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-2344. doi: 10.1056/NEJMoa2028836.

Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;384(1):20-30. doi: 10.1056/NEJMoa2030340.

Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8.

Langer-Gould A, Smith JB, Gonzales EG, Castillo RD, Figueroa JG, Ramanathan A, et al. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Int J Infect Dis. 2020;99:291-297. doi: 10.1016/j.ijid.2020.07.081.

Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA. 2020;324(8):799-801. doi: 10.1001/jama.2020.13372.

T.C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü Bilimsel Danışma Kurulu çalışması (2020). COVID-19 (SARS-CoV-2 enfeksiyonu) Erişkin hasta tedavisi (2020). (14.01.2021 tarihinde https://covid19.saglik.gov.tr/Eklenti/39061/0/covid-19rehberieriskinhastatedavisipdf.pdf adresinden ulaşılmıştır).

T.C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü Bilimsel Danışma Kurulu çalışması (2020). COVID-19 (SARS-CoV-2 enfeksiyonu) Antisitokin-antiinflamatuar tedaviler, koagülopati yönetimi (2020). (14.01.2021 tarihinde https://covid19.saglik.gov.tr/Eklenti/39296/0/covid-19rehberiantisitokin-antiinflamatuartedavilerkoagulopatiyonetimipdf.pdf adresinden ulaşılmıştır).

NIH (2010). COVID-19 Treatment Guidelines (2020). (17.01.2021. tarihinde https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf adresinden ulaşılmıştır).

Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Version 3.6.0. 17.01.2021 tarihinde https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ adresinden ulaşılmıştır).